Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Sigurdis Haraldsdottir"'
Autor:
Hanlee P. Ji, Lan Zhao, Susan M. Grimes, Stephanie U. Greer, Carlos Suárez, Erik S. Hopmans, Alison Almeda, GiWon Shin, Hojoon Lee, Laura Miotke, Sigurdis Haraldsdottir
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-18 (2021)
Genome Medicine
Genome Medicine
Colorectal carcinomas (CRCs) which have lost DNA mismatch repair display hypermutability evident in a molecular phenotype called microsatellite instability (MSI). These mismatch repair deficient tumors are thought to lack widespread genomic instabili
Autor:
Kristen K. Ciombor, Yoanna Pumpalova, Christina Wu, Tanios Bekaii-Saab, Mohamad Bassam Sonbol, Jordan Berlin, Gregory B. Lesinski, Zhengjia Chen, Bassel F. El-Rayes, Ibrahim Halil Sahin, Amber Draper, Subir Goyal, Sigurdis Haraldsdottir, Satya Das, Daniel H. Ahn
Publikováno v:
Oncologist
Background Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. Materials an
Autor:
Julie W. Reeser, Jarred Burkart, Robert Wesolowski, Manisha H. Shah, Sameek Roychowdhury, Dwight H. Owen, Sherif Abdel-Misih, Eric Samorodnitsky, Sigurdis Haraldsdottir, Bhavana Konda, Amy Smith
Publikováno v:
Journal of the National Comprehensive Cancer Network. 16:1035-1040
Mutations in the RAS/RAF/MEK/ERK pathway leading to constitutive activation and uncontrolled cellular growth have been identified in various human malignancies, making this pathway a target for potential therapeutics. The activating BRAFV600E mutatio
Publikováno v:
Cold Spring Harbor Molecular Case Studies
Although combination therapy with RAF and EGFR inhibitors has improved the survival outcomes of patients with BRAF-mutated colorectal cancer (CRC), acquired resistance invariably develops. The mechanisms of acquired resistance to RAF inhibitors have
Autor:
Thor Aspelund, Jon G. Jonasson, Matthías Halldórsson, Michael Hauptmann, Sigurdis Haraldsdottir, Kristín Huld Haraldsdóttir, Vilmundur Gudnason, Petur Snaebjornsson, Elias F. Gudmundsson
Publikováno v:
Scandinavian Journal of Gastroenterology. 53:972-975
Mismatch repair deficient (dMMR) colorectal cancer (CRC) is caused by inactivation of the MMR DNA repair system, most commonly via epigenetic inactivation of the MLH1 gene, and these tumors occur most frequently in the right colon. The objective was
Autor:
Christina Wu, Richard M. Goldberg, Xueliang Pan, Albert de la Chapelle, Peter G. Shields, Heather Hampel, Tanios Bekaii-Saab, Daniel Y. Weng, Sigurdis Haraldsdottir, Wendy L. Frankel
Publikováno v:
Genetics in medicine : official journal of the American College of Medical Genetics
Mismatch repair–deficient (dMMR) colorectal cancer (CRC) is caused by Lynch syndrome (LS) in 3% and sporadic inactivation of MLH1 by hypermethylation (MLH1-hm) in 12% of cases. It is not clear whether outcomes between LS-associated and MLH1-hm CRC
Publikováno v:
Molecular Case Studies. 6:a005140
Although combination therapy with RAF and EGFR inhibitors has improved the survival outcomes of patients with BRAF-mutated colorectal cancer (CRC), acquired resistance invariably develops. The mechanisms of acquired resistance to RAF inhibitors have
Autor:
Tanios Bekaii-Saab, Lai Wei, Jeffrey S. Rose, Christina Wu, Richard M. Goldberg, Sigurdis Haraldsdottir
Publikováno v:
Journal of Cancer Therapy. :948-955
Introduction: Panitumumab is an EGFR inhibitor approved for use in metastatic refractory colorectal cancer. It is unclear whether patients who have progressed on cetuximab may benefit from subsequent panitumumab therapy. This retrospective analysis w
Autor:
Emily H. Turner, Sheena M. Scroggins, Mallory Beightol, Paul J. Goodfellow, Christina Smith, Heather Hampel, Rachel Pearlman, Albert de la Chapelle, William M. Grady, Edward H. Lin, Mark Arnold, Jonathan F. Tait, Stacey A. Cohen, Colin C. Pritchard, David E. Cohn, Ted Gooley, Sigurdis Haraldsdottir, Stephen J. Salipante, Angela Jacobson
Publikováno v:
Gastroenterology. 151:440-447.e1
Background & Aims Some colorectal and endometrial tumors with microsatellite instability not attributable to MLH1 hypermethylation or germline mutations contain 2 or more somatic mutations in genes encoding mismatch repair (MMR) proteins. We sought t
Autor:
Stefan Haraldsson, Sigurdis Haraldsdottir, Sylvia Einarsdottir, Jon G. Jonasson, Richard M. Goldberg, Kari Stefansson, Tanios Bekaii-Saab, Patrick Sulem, Asgeir Sigurdsson, Heather Hampel, Albert de la Chapelle, Gisli Masson, Colin C. Pritchard, Birte Kehr, Thorunn Rafnar, Ahmet Yilmaz, Megan P. Hitchins, Wendy L. Frankel, Daniel Weng, Petur Snaebjornsson
Publikováno v:
Journal of Clinical Oncology. 34:1542-1542
1542Background: Lynch syndrome (LS) is caused by germline mutations in mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or EPCAM, and is associated withincreased cancer risk. The incidence of LS in Iceland is unknown. We investigated the incidenc